404 related articles for article (PubMed ID: 17486079)
1. Targeting the function of the HER2 oncogene in human cancer therapeutics.
Moasser MM
Oncogene; 2007 Oct; 26(46):6577-92. PubMed ID: 17486079
[TBL] [Abstract][Full Text] [Related]
2. HER2 (erbB-2)-targeted effects of the omega-3 polyunsaturated fatty acid, alpha-linolenic acid (ALA; 18:3n-3), in breast cancer cells: the "fat features" of the "Mediterranean diet" as an "anti-HER2 cocktail".
Menéndez JA; Vázquez-Martín A; Ropero S; Colomer R; Lupu R
Clin Transl Oncol; 2006 Nov; 8(11):812-20. PubMed ID: 17134970
[TBL] [Abstract][Full Text] [Related]
3. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.
Moasser MM
Oncogene; 2007 Oct; 26(45):6469-87. PubMed ID: 17471238
[TBL] [Abstract][Full Text] [Related]
4. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
5. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
Sliwkowski MX; Lofgren JA; Lewis GD; Hotaling TE; Fendly BM; Fox JA
Semin Oncol; 1999 Aug; 26(4 Suppl 12):60-70. PubMed ID: 10482195
[TBL] [Abstract][Full Text] [Related]
6. HER2: biology, detection, and clinical implications.
Gutierrez C; Schiff R
Arch Pathol Lab Med; 2011 Jan; 135(1):55-62. PubMed ID: 21204711
[TBL] [Abstract][Full Text] [Related]
7. Biological considerations and clinical applications of new HER2-targeted agents.
Higa GM; Singh V; Abraham J
Expert Rev Anticancer Ther; 2010 Sep; 10(9):1497-509. PubMed ID: 20836684
[TBL] [Abstract][Full Text] [Related]
8. Application and potential limitations of animal models utilized in the development of trastuzumab (Herceptin): a case study.
Pegram M; Ngo D
Adv Drug Deliv Rev; 2006 Aug; 58(5-6):723-34. PubMed ID: 16876287
[TBL] [Abstract][Full Text] [Related]
9. Targeting HER2: recent developments and future directions for breast cancer patients.
Wang SC; Zhang L; Hortobagyi GN; Hung MC
Semin Oncol; 2001 Dec; 28(6 Suppl 18):21-9. PubMed ID: 11774202
[TBL] [Abstract][Full Text] [Related]
10. An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance.
Mitra D; Brumlik MJ; Okamgba SU; Zhu Y; Duplessis TT; Parvani JG; Lesko SM; Brogi E; Jones FE
Mol Cancer Ther; 2009 Aug; 8(8):2152-62. PubMed ID: 19671734
[TBL] [Abstract][Full Text] [Related]
11. HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy?
Latif Z; Watters AD; Dunn I; Grigor K; Underwood MA; Bartlett JM
Eur J Cancer; 2004 Jan; 40(1):56-63. PubMed ID: 14687790
[TBL] [Abstract][Full Text] [Related]
12. Her2-positive breast cancer: herceptin and beyond.
Dean-Colomb W; Esteva FJ
Eur J Cancer; 2008 Dec; 44(18):2806-12. PubMed ID: 19022660
[TBL] [Abstract][Full Text] [Related]
13. Inhibitors of HER2/neu (erbB-2) signal transduction.
Arteaga CL; Chinratanalab W; Carter MB
Semin Oncol; 2001 Dec; 28(6 Suppl 18):30-5. PubMed ID: 11774203
[TBL] [Abstract][Full Text] [Related]
14. Targeting the human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer: recent advances and future directions.
Nanda R
Rev Recent Clin Trials; 2007 May; 2(2):111-6. PubMed ID: 18473995
[TBL] [Abstract][Full Text] [Related]
15. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).
Reid A; Vidal L; Shaw H; de Bono J
Eur J Cancer; 2007 Feb; 43(3):481-9. PubMed ID: 17208435
[TBL] [Abstract][Full Text] [Related]
16. Targeting endothelin A receptor enhances anti-proliferative and anti-invasive effects of the HER2 antibody trastuzumab in HER2-overexpressing breast cancer cells.
Fischgräbe J; Götte M; Michels K; Kiesel L; Wülfing P
Int J Cancer; 2010 Aug; 127(3):696-706. PubMed ID: 19960438
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
18. New molecule-targeting therapy with herceptin (trastuzumab), an anti-HER2 (c-erB-2) monoclonal antibody.
Sakamoto G; Mitsuyama S
Breast Cancer; 2000; 7(4):350-7. PubMed ID: 11114864
[No Abstract] [Full Text] [Related]
19. Antitumor activity of a monoclonal antibody targeting major histocompatibility complex class I-Her2 peptide complexes.
Jain R; Rawat A; Verma B; Markiewski MM; Weidanz JA
J Natl Cancer Inst; 2013 Feb; 105(3):202-18. PubMed ID: 23300219
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin.
Kim SY; Kim HP; Kim YJ; Oh DY; Im SA; Lee D; Jong HS; Kim TY; Bang YJ
Int J Oncol; 2008 Jan; 32(1):89-95. PubMed ID: 18097546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]